Hypothyroidism manifesting as multiple cranial neuropathies: a case report

Matthias Hepprich1†, Johannes Lorscheider2†, Nils Peters2 and Matthias Johannes Betz1

Abstract

Introduction: The clinical picture of hypothyroidism, including neurological symptoms, can be multiform, which may delay or hamper the correct diagnosis.

Case presentation: We present an uncommon clinical presentation of a 38-year-old Caucasian man with mild facial palsy on the left side, uvular deviation to the left with preserved gag reflex, tongue deviation to the left, lingual dysarthria, and xerosis by severe hypothyroidism. Blood tests on admission showed elevated serum creatinine of 151 μmol/L (glomerular filtration rate 47 ml/min/1.7 CKD-EPI [Chronic Kidney Disease Epidemiology Collaboration equation]), increased creatinine phosphokinase activity (1243 U/L), markedly elevated thyroid-stimulating hormone (292.2 mIU/L), low free thyroxine level (1.1 pmol/L), and free triiodothyronine level below the limit of detection (< 0.4 pmol/L). Results of brain magnetic resonance imaging and renal ultrasound were unremarkable. Lumbar puncture revealed a normal cell count in cerebrospinal fluid, with an increased protein level of 758 mg/L and a cerebrospinal fluid/serum albumin ratio of 10.5 × 10−3/L (reference range < 6.7). Further diagnostic workup did not reveal any inflammatory or infectious systemic pathologies as an underlying cause. The patient’s neurological symptoms, as well as laboratory findings including renal function, creatinine phosphokinase, and initially altered blood lipid levels, normalized with levothyroxine substitution.

Conclusions: Multiple cranial neuropathy is an uncommon clinical finding in hypothyroidism, which is an important differential diagnosis in the workup of new neurological deficits.

Keywords: Hypothyroidism, Cranial neuropathy, Myxedema, Hashimoto, Myopathy

Background

Thyroid hormone (TH) is essential for the function and regulation of cellular metabolism in virtually all mammalian cells. Additionally, TH is of paramount importance for neurocognitive development. Signs and symptoms of severe hypothyroidism concerning the cardiovascular system or metabolism, namely bradycardia, edema, or reduced metabolic rate, are well known. Moreover, neurological complications such as lethargy and impairment of attention, as well as diffuse peripheral neuropathy and entrapment neuropathy, are common [1]. We present a case of a patient with severe hypothyroidism presenting with a rare neurological manifestation.

Case presentation

A 38-year-old Caucasian man presented to the emergency department of our hospital with a 3-week history of dysarthria and facial weakness on the left side. A few weeks before symptom onset, he had undergone surgery for carpal tunnel syndrome on the right side. Apart from increasing fatigue and continuous weight gain of almost 20 kg over the last 2 years, his medical and family history was unremarkable. His clinical examination revealed a mild lower motor neuron facial palsy on the left, uvular deviation to the left with preserved gag reflex, tongue deviation to the left, lingual dysarthria, and xerosis. His pupils and eye movements were normal, his power and sensation for all qualities including vibration sense were preserved, his reflexes were present symmetrically, and he had no ataxia. Facial fullness and edematous extremities were noted. His mucous membranes were unremarkable, but his skin was dry. His vital parameters were normal apart from an increased body mass index (31.6 kg/m²) and
hypothermic tympanic temperature of 35.6 °C (blood pressure 127/79 mmHg, heart rate 70 beats/min).

His blood test results on admission showed elevated serum creatinine of 151 μmol/L (glomerular filtration rate 47 ml/min/1.7 CKD-EPI [Chronic Kidney Disease Epidemiology Collaboration equation]) and increased creatinine phosphokinase (CK) activity (1243 U/L). Results of brain magnetic resonance imaging (MRI) and renal ultrasound were unremarkable. Cerebrospinal fluid (CSF) analysis revealed a normal cell count but increased protein levels of 758 mg/L and a CSF/serum albumin ratio of 10.5 × 10⁻³/L (reference range < 6.7) without signs of intrathecal immunoglobulin production or oligoclonal bands. Results of serological testing were unremarkable. MRI of the brain did not show any pathologic lesions or contrast enhancement, especially within the cranial nerves. Multiple cranial neuropathy was presumed, and the patient was admitted to the department of neurology.

On the following day, routinely performed thyroid function tests detected markedly elevated levels of thyroid-stimulating hormone (TSH) (292.2 mIU/L), low free thyroxine levels (1.1 pmol/L), and free triiodothyronine levels below the limit of detection (< 0.4 pmol/L). A diagnosis of overt hypothyroidism was made, and levothyroxine therapy in a dose of 100 μg/d (1.0 μg/kg body weight, 1.3 μg per ideal body weight) was started after hypocortisolism was excluded. Ultrasound revealed a small thyroid gland (4.8 ml) with an inhomogeneous pattern but without signs of focal lesions. Further diagnostic workup showed a markedly reduced basal metabolic rate on indirect calorimetry (1380 kcal/d, reference 1950 kcal/d) and elevated antibodies against thyroid peroxidase (495 IU/mL, reference range < 34 IU/mL). When the patient was discharged 1 week after admission, his symptoms were unimproved. Six weeks later, the patient was seen in our outpatient clinic and reported a substantial improvement of speech quality and general well-being. On clinical examination, no residual pathologic signs were observed. The patient’s levothyroxine dosage was eventually increased to 150 μg/d, and his levels of TSH and free T4 normalized (Table 1). At the following visit, 5 months after initiation of levothyroxine substitution, the patient’s facial features had changed substantially, and all his neurologic symptoms had completely resolved. A loss of 2 kg body weight was noted. The remainder of his physical examination was unremarkable.

### Table 1 Laboratory results at initial presentation and follow-up visits (in bold values below or above reference)

|                         | Initial presentation | 6 Weeks later | 5 Months later | Reference range |
|-------------------------|---------------------|--------------|---------------|----------------|
| Levothyroxine dosage, μg/d | –                   | 100.00       | 150.00        |                |
| Leukocytes, 10⁹/L        | 6.06                | 6.67         | 7.80          | 3.5–10.0       |
| Hemoglobin, g/L          | 148.00              | 138.00       | 144.00        | 140–180        |
| Creatinine, μmol/L       | 151.00              | 99.00        | 91.00         | 49–97          |
| Urea, mmol/L             | 7.90                | 6.40         | 5.00          | 3.2–7.3        |
| ASAT, U/L                | 59.00               | 26.00        | nd            | 11–34          |
| ALAT, U/L                | 33.00               | 31.00        | nd            | 9–59           |
| LDH, U/L                 | 417.00              | 203.00       | nd            | 135–225        |
| Creatine phosphokinase (CK), U/L | 1243.00          | 106.00       | nd            | 50–200         |
| CK-MB, μg/L              | 18.40               | nd           | nd            | < 5.0 μg/L     |
| Triglycerides, mmol/L    | 1.57                | 1.74         | 0.72          | < 1.7          |
| Total cholesterol, mmol/L| 6.71                | 3.18         | 4.05          | 3.0–5.2        |
| HDL cholesterol, mmol/L  | 1.63                | 0.85         | 1.37          | 0.9–2.2        |
| LDL cholesterol, mmol/L  | 4.37                | 1.54         | 2.35          | 16.0–3.40      |
| Thyrotropin (TSH), mIU/L  | 292.00              | 2.69         | 2.19          | 0.332–4.490    |
| Free T4, pmol/L          | 1.10                | 21.00        | 19.30         | 11.6–22.0      |
| Free T3, pmol/L          | < 0.4               | 5.50         | 5.40          | 2.6–5.6        |
| Total T4, nmol/L         | 6.00                | nd           | nd            | 66–181         |
| Total T3, nmol/L         | < 0.3               | nd           | nd            | 1.2–3.2        |
| Cortisol, nmol/L         | 449.00              | nd           | nd            | 80–638         |
| Glucose, mmol/L          | 5.00                | nd           | 4.50          | 3.8–6.1        |
| Glycated hemoglobin A1c, %| 5.30                | nd           | nd            | 4.8–5.9        |

**Abbreviations:** ALAT Alanine aminotransferase, ASAT Aspartate aminotransferase, CK-MB Muscle/brain creatine kinase, HDL High-density lipoprotein, LDH Lactate dehydrogenase, LDL Low-density lipoprotein, nd Not determined, T3 Triiodothyronine, T4 Thyroxine, TSH Thyroid-stimulating hormone
Laboratory analysis showed normal levels of thyroid hormones and TSH as well as normal creatinine phosphokinase and kidney parameters. Increased total and low-density cholesterol levels at initial presentation also had normalized at the 5-month follow-up visit.

**Discussion**

We report an unusual case of severe hypothyroidism due to autoimmune thyroiditis with myxedema, neuromyopathy, and renal affection. Hypothyroidism is the leading thyroid disorder worldwide, with autoimmune causation being the most common [2], and a prevalence of 3.05% in Europe with a female preponderance [3]. Typical signs of hypothyroidism such as fatigue, weight gain, hypothermia, dry skin, and myxedema with facial fullness, as in our patient, are well known but are neither sensitive nor specific, and the clinical picture can vary substantially with a slow long-term progression often leading to non- or misdiagnosis [2].

Thyroid hormones are ubiquitously required for development and maintenance of cellular functions and are paramount for the development of the central nervous system [4]. Thus, thyroid hormone deficiency can affect the central and peripheral nervous systems. A decline or slowing of neurocognitive functions (memory loss, ataxia), probably due to altered synaptic plasticity, is commonly observed in patients with myxedema, but it is often only partially reversible even under appropriate treatment [2].

The long duration of initial hypothyroid symptoms starting already 2 years before cranial nerve symptoms occurred, with extremely low thyroid hormone levels at presentation, may be an explanation for the clinical symptoms of our patient. Most of the patients may present at earlier stages before onset of symptoms. When untreated, severe hypothyroidism can be life-threatening and can lead to myxedema coma. This is usually precipitated by an additional hit, such as an acute infection, trauma, or other forms of stress [11]. Shortly before his initial presentation, our patient underwent surgery for carpal tunnel syndrome, which may have been prevented or could have led to an earlier diagnosis of the underlying thyroid disorder.

**Conclusions**

As hypothyroidism can cause a wide variety of neurological symptoms, any unclear neurological findings should prompt thyroid function testing. Multiple cranial neuropathy is a rare manifestation of hypothyroidism and was fully reversible in our patient with levothyroxine substitution.

**Abbreviations**

ALAT: Alanine aminotransferase; ASAT: Aspartate aminotransferase; CK-MB: Muscle/brain creatine kinase; CSF: Cerebrospinal fluid; HDL: High-density lipoprotein; LDH: Lactate dehydrogenase; LDL: Low-density lipoprotein; MRI: Magnetic resonance imaging; T3: Triiodothyronine; T4: Thyroxine; TH: Thyroid hormone; TSH: Thyroid-stimulating hormone

**Acknowledgements**

We thank the patient for giving his informed consent to publish this case report and Joe Monaghan for proofreading our article.

**Authors’ contributions**

MH and JL contributed equally to this article. All authors were involved in the clinical course and treatment of the patient as well as in the entire writing process of the article. All authors read and approved the final manuscript.

**Funding**

No targeted funding.

**Ethics approval and consent to participate**

This case report was written in accordance with the recommendations of the Declaration of Helsinki. The patient is described anonymously and gave written informed consent for the publication of this case report and any
accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.

Competing interests
The authors declare that they have no competing interests.

Author details
1 Department of Endocrinology, Diabetes and Metabolism, University Hospital Basel and University of Basel, Petersgraben 4, 4031 Basel, Switzerland.
2 Department of Neurology, University Hospital Basel and University of Basel, Petersgraben 4, Basel 4031, Switzerland.

Received: 10 January 2019 Accepted: 16 May 2019
Published online: 13 June 2019

References
1. Wood-Allum CA, Shaw PJ. Thyroid disease and the nervous system. Handb Clin Neurol. 2014;120:703–35.
2. Chaker L, Bianco AC, Jonklaas J, Peeters RP. Hypothyroidism. Lancet. 2017;390(10101):1550–62.
3. Garmendia Madariaga A, Santos Palacios S, Guillen-Grima F, Galofre JC. The incidence and prevalence of thyroid dysfunction in Europe: a meta-analysis. J Clin Endocrinol Metab. 2014;99(3):923–31.
4. Chan S, Kelby MD. Thyroid hormone and central nervous system development. J Endocrinol. 2000;165(1):1–8.
5. Nyström E, Hamberger A, Lindstedt G, Lundquist C, Wikkelso C. Cerebrospinal fluid proteins in subclinical and overt hypothyroidism. Acta Neurol Scand. 1997;95(5):311–4.
6. Khedr EM, El Toony LF, Tarhan MN, Abdella G. Peripheral and central nervous system alterations in hypothyroidism: electrophysiological findings. Neuropsychobiology. 2000;41(2):88–94.
7. Gupta N, Arora M, Sharma R, Arora KS. Peripheral and central nervous system involvement in recently diagnosed cases of hypothyroidism: an electrophysiological study. Ann Med Health Sci Res. 2016;6(5):261–6.
8. Shirabe T, Tawara S, Terao A, Araki S. Myxoedematous polyneuropathy: a light and electron microscopic study of the peripheral nerve and muscle. J Neurol Neurosurg Psychiatry. 1975;38(3):241–7.
9. Iglesias P, Bajo MA, Selgas R, Diez JJ. Thyroid dysfunction and kidney disease: an update. Rev Endocr Metab Disord. 2017;18(1):131–44.
10. Hataya Y, Igarashi S, Yamashita T, Komatsu Y. Thyroid hormone replacement therapy for primary hypothyroidism leads to significant improvement of renal function in chronic kidney disease patients. Clin Exp Nephrol. 2013;17(4):525–31.
11. Wiersinga WM. Myxedema and coma (severe hypothyroidism). In: De Groot LJ, Chrousos G, Dungan K, Feingold KR, Grossman A, Hershman JM, et al., editors. Endotext. South Dartmouth: MDText, Inc.; 2000 [updated 25 Apr 2018].

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.